ChromoGenics AB reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported sales was SEK 2.69 million compared to SEK 5.81 million a year ago. Revenue was SEK 3.47 million compared to SEK 6.73 million a year ago. Net loss was SEK 16.6 million compared to SEK 12.44 million a year ago. Basic loss per share from continuing operations was SEK 4. Diluted loss per share from continuing operations was SEK 4.
For the full year, sales was SEK 15.7 million compared to SEK 24.44 million a year ago. Revenue was SEK 19.61 million compared to SEK 29.35 million a year ago. Net loss was SEK 52.51 million compared to SEK 56.98 million a year ago. Basic loss per share from continuing operations was SEK 19.8 compared to SEK 158.8 a year ago. Diluted loss per share from continuing operations was SEK 19.8 compared to SEK 158.8 a year ago.